艾司氯胺酮在围术期器官保护作用中的研究进展

doi:10.16352/j.issn.1001-6325.2026.10.1429

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (10): 1429-1434.doi: 10.16352/j.issn.1001-6325.2026.10.1429

艾司氯胺酮在围术期器官保护作用中的研究进展

录亚鹏, 王迎斌^*, 路文胜

兰州大学第二医院麻醉科,甘肃兰州 730030

收稿日期:2025-07-22 修回日期:2025-11-25 出版日期:2026-10-05 发布日期:2026-09-18
通讯作者: ^*wangyingbin6@163.com
基金资助:
甘肃省自然科学基金(25JRRA592)

Research progress on the organ- protective effects of esketamine in the perioperative period

LU Yapeng, WANG Yingbin^*, LU Wensheng

Department of Anestheiology, Lanzhou University Second Hospital, Lanzhou 730000, China

Received:2025-07-22 Revised:2025-11-25 Online:2026-10-05 Published:2026-09-18
Contact: ^*wangyingbin6@163.com

摘要/Abstract

摘要： 艾司氯胺酮(esketamine)作为氯胺酮的右旋异构体,主要通过非竞争性拮抗N-甲基-D-天冬氨酸(NMDA)受体发挥生物学作用。作为一种新型静脉麻醉药,艾司氯胺酮可通过抑制炎性反应与氧化应激、调节钙超载、影响肠道菌群、调控细胞自噬及抑制细胞铁死亡等多种机制发挥器官保护作用,有望成为改善围术期器官损伤的新选择。

关键词: 艾司氯胺酮, 围术期, 保护器官

Abstract: Esketamine, the dextro-isomer of ketamine, primarily acts as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Beyond its anesthetic properties, esketamine confers organ protection through multiple mechanisms, including the suppression of inflammatory responses and oxidative stress, regulation of calcium overload, modulation of gut microbiota, control of cellular autophagy, and inhibition of ferroptosis. Consequently, it emerges as a promising therapeutic strategy for mitigating perioperative organ injury.

Key words: esketamine, perioperative period, organ protection

中图分类号:

录亚鹏, 王迎斌, 路文胜. 艾司氯胺酮在围术期器官保护作用中的研究进展[J]. 基础医学与临床, 2026, 46(10): 1429-1434.

LU Yapeng, WANG Yingbin, LU Wensheng. Research progress on the organ- protective effects of esketamine in the perioperative period[J]. Basic & Clinical Medicine, 2026, 46(10): 1429-1434.

参考文献

[1] 袁培根, 陈顺利, 单鸳露, 等. 艾司氯胺酮减轻大鼠骨骼肌缺血再灌注损伤[J]. 基础医学与临床, 2023,12:1822-1826.
[2] Yaghoobi Z, Ataei S, Riahi E, et al. Neuroprotective effects of MK-801 against cerebral ischemia reperfusion[J]. Heliyon, 2024,10:e33821. doi:10.1016/j.heliyon.2024.e33821.
[3] Zou S, Sun H, Peng Y, et al. Mu-opioid receptor alleviated ferroptosis in hepatic ischemia-reperfusion injury via the HIF-1α/KCNQ1OT1 axis[J]. Am J Physiol Cell Physiol, 2023,324:C927-C940.
[4] Yi S, Cao H, Zheng W, et al. Targeting the opioid remifentanil: Protective effects and molecular mechanisms against organ ischemia-reperfusion injury[J]. Biomed Pharmacother, 2023,167:115472. doi:10.1016/j.biopha.2023.115472.
[5] Bi Z, Kong L, Zhao J, et al. Positive effects of low-dose S-ketamine on preventing myocardial injury after thoracoscopic lobectomy in patients aged 70 to 85[J]. BMC Anesthesiol, 2024,24:103. doi:10.1186/s12871-024-02491-z.
[6] Ouyang J, Xiao W, Wu D, et al. Esketamine alleviated cardiomyocyte ferroptosis induced by oxygen-glucose deprivation/reoxygenation (OGD/R) via cyclic GMP-AMP synthase interactor[J]. Cytotechnology, 2025,77:57. doi:10.1007/s10616-025-00723-9.
[7] Zhang Y, Lu Q, Hu H, et al. Esketamine alleviates hypoxia/reoxygenation injury of cardiomyocytes by regulating TRPV1 expression and inhibiting intracellular Ca(2+) concentration[J]. Clinics (Sao Paulo), 2024,79:100363. doi:10.1016/j.clinsp.2024.100363.
[8] Lv XL, Liu Q, Yu JP, et al. Effect of subanesthetic dose of esketamine on liver function following microvascular reconstruction for head and neck cancer: A randomized controlled Trial[J]. Drug Des Devel Ther, 2025,19:3971-3981.
[9] Ge X, Gu Y, Wang W, et al. Corynoline alleviates hepatic ischemia-reperfusion injury by inhibiting NLRP3 inflammasome activation through enhancing Nrf2/HO-1 signaling[J]. Inflamm Res, 2024,73:2069-2085.
[10] Xu W, Wang P, Wang D, et al. S-ketamine alleviates carbon tetrachloride-induced hepatic injury and oxidative stress by targeting the Nrf2/HO-1 signaling pathway[J]. Can J Physiol Pharmacol, 2021,99:1308-1315.
[11] Tang Y, Liu Y, Zhou H, et al. Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation[J]. Exp Neurol, 2023,366:114436. doi:10.1016/j.expneurol.2023.114436.
[12] Li H, Hu W, Wu Z, et al. Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation[J]. Eur J Pharmacol, 2024,983:177014. doi:10.1016/j.ejphar.2024.177014.
[13] Gao Y, Li L, Zhao F, et al. Esketamine at a clinical dose attenuates cerebral ischemia/reperfusion injury by inhibiting AKT signaling pathway to facilitate microglia M2 polarization and autophagy[J]. Drug Des Devel Ther, 2025,19:369-387.
[14] Wang L, Ma B, Zhang J. Effect of subclinical esketamine on NLRP3 and cognitive dysfunction in elderly ischemic stroke patients[J]. Open Med (Wars), 2025,20:20251193. doi:10.1515/med-2025-1193
[15] Hu W, Luo J, Li H, et al. Identification of key genes in esketamine′s therapeutic effects on perioperative neurocognitive disorders via transcriptome sequencing[J]. Drug Des Devel Ther, 2025,19:981-1000.
[16] Wu Y, Zhang Y, Xie B, et al. Esketamine mitigates cognitive impairment following exposure to LPS by modulating the intestinal flora/subdiaphragmatic vagus nerve/spleen axis[J]. Int Immunopharmacol, 2024,126:111284. doi:10.1016/j.intimp.2023.111284.
[17] Fu M, Xu R, Chen G, et al. Postoperative esketamine improves ventilation after video-assisted thoracoscopic lung resection: A double-blinded randomized controlled trial[J]. Heliyon, 2024,10:e25100. doi:10.1016/j.heliyon.2024.e25100.
[18] Cai SY, Liu A, Xie WX, et al. Esketamine mitigates mechanical ventilation-induced lung injury in chronic obstructive pulmonary disease rats via inhibition of the MAPK/NF-κB signaling pathway and reduction of oxidative stress[J]. Int Immunopharmacol, 2024,139:112725. doi:10.1016/j.intimp.2024.112725.
[19] Shi J, Song S, Wang Y, et al. Esketamine alleviates ferroptosis-mediated acute lung injury by modulating the HIF-1α/HO-1 pathway[J]. Int Immunopharmacol, 2024,142(Pt A):113065. doi:10.1016/j.intimp.2024.113065.
[20] Qiao D, Liu W, Xue H, et al. Comparison of the effects of esketamine/midazolam and remifentanil/midazolam on respiratory mechanics in mechanically ventilated patients with acute respiratory distress syndrome[J]. BMC Anesthesiol, 2025,25:339. doi:10.1186/s12871-025-03211-x.
[21] 刘永, 钟祥鹏, 张亮,等. 艾司氯胺酮联合舒芬太尼PCIA对肾移植患者术后镇痛效果和早期肾功能的影响[J]. 川北医学院学报,2023,38:1322-1325.
[22] 咸淑悦, 熊冰睿, 方清,等. 艾司氯胺酮对大鼠脓毒症急性肾损伤的影响及自噬在其中的作用[J]. 中华麻醉学杂志,2021,41:1000-1004.
[23] Tao QY, Liu D, Wang SJ, et al. Effects of esketamine combined with dexmedetomidine on early postoperative cognitive function in elderly patients undergoing lumbar spinal surgery: A double-blind randomized controlled clinical trial[J]. Drug Des Devel Ther, 2024,18:5461-5472.
[24] Zhang CL, Yan Y, Zhang Y, et al. Effects of esketamine combined with dexmedetomidine on postoperative delirium and quality of recovery in elderly patients undergoing thoracoscopic radical lung cancer surgery: a randomized controlled trial[J]. CNS Spectr, 2024:1-10. doi:10.1017/S1092852924002177.
[25] 邵先红, 朱勃朗, 王纯辉,等. 瑞马唑仑联合艾司氯胺酮对剖宫产手术麻醉效果和精神症状的影响[J]. 临床麻醉学杂志,2024,40:719-722.

艾司氯胺酮在围术期器官保护作用中的研究进展

Research progress on the organ- protective effects of esketamine in the perioperative period

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	杜金知, 倪文洋, 朱荣宇, 孟治寿, 杨建新. 艾司氯胺酮缓解膝骨关节炎大鼠疼痛[J]. 基础医学与临床, 2026, 46(8): 1096-1102.
[2]	童媛媛, 熊蔚, 李享佳卉, 陈良, 范议方, 韩如泉, 谢思宁. 地氟烷全身麻醉在帕金森病患者脑深部电刺激术中的应用[J]. 基础医学与临床, 2025, 45(7): 952-957.
[3]	朱倩梅, 李清扬, 车璐, 黄宇光. 疾病相关的肠道菌群微生态在肺损伤形成的机制研究[J]. 基础医学与临床, 2025, 45(5): 681-685.
[4]	杨文, 李勇, 杨淖绚. 小剂量艾司氯胺酮联合舒芬太尼减轻全髋关节置换术老年患者围手术期炎性反应[J]. 基础医学与临床, 2025, 45(1): 60-64.
[5]	朱倩梅, 刘子嘉, 谭刚, 申乐, 黄宇光. 加速康复外科与围术期管理课程在研究生教学中的探索实践[J]. 基础医学与临床, 2024, 44(2): 276-280.
[6]	臧晗, 胡嫒, 许轩奇, 许力. 老年单侧全髋关节置换术围术期输血风险预测模型的构建[J]. 基础医学与临床, 2024, 44(1): 98-102.
[7]	袁培根, 陈顺利, 单鸳露, 薛彬彬, 叶玉柱, 林丽娜. 艾司氯胺酮减轻大鼠骨骼肌缺血再灌注损伤[J]. 基础医学与临床, 2023, 43(12): 1822-1826.
[8]	董德鑫, 张玉石, 严维刚, 石冰冰. 改良加速康复外科在腹腔镜肾部分切除术中的应用[J]. 基础医学与临床, 2023, 43(11): 1702-1706.
[9]	任海强, 李雷, 杨旺燕, 杜鹃, 姜丹丹, 闫莉, 傅润乔. 小剂量艾司氯胺酮联合右美托咪定在老年患者椎体成形术麻醉中的应用[J]. 基础医学与临床, 2022, 42(6): 950-954.
[10]	戎玉兰, 史成梅, 郭向阳. DNA损伤修复研究进展及其对围术期认知功能障碍的影响[J]. 基础医学与临床, 2022, 42(4): 675-678.
[11]	何小义, 邹学军, 刑浩然. 目标导向液体治疗用于加速康复外科的新进展[J]. 基础医学与临床, 2020, 40(7): 995-998.
[12]	雷成, 梅弘勋, 韩如泉. 合并血友病患者神经外科围术期处理[J]. 基础医学与临床, 2020, 40(11): 1534-1536.
[13]	陈志刚岳红丽赵岩韩如泉. 脊柱脊髓手术围术期镇痛管理进展[J]. 基础医学与临床, 2017, 37(4): 571-575.
[14]	裴丽坚阮侠黄宇光罗爱伦郭文娟王蕾王科研张玉石李汉忠. 嗜铬细胞瘤10年307例围手术期麻醉临床分析[J]. 基础医学与临床, 2014, 34(5): 695-698.